Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables: 2018-2025

  • China SXT Pharmaceuticals' Receivables fell 72.24% to $119.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $548.0 billion, marking a year-over-year decrease of 35.92%. This contributed to the annual value of $3.5 million for FY2025, which is 11.57% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Receivables stood at $119.1 billion for Q3 2025, which was up 3,409,961.81% from $3.5 million recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Receivables ranged from a high of $428.9 billion in Q3 2024 and a low of $3.1 million during Q1 2023.
  • Moreover, its 3-year median value for Receivables was $59.5 billion (2025), whereas its average is $162.4 billion.
  • In the last 5 years, China SXT Pharmaceuticals' Receivables climbed by 13.54% in 2021 and then plummeted by 72.24% in 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Receivables (Quarterly) stood at $6.9 million in 2021, then fell by 22.72% to $4.7 million in 2022, then slumped by 33.69% to $426.3 billion in 2023, then increased by 0.62% to $428.9 billion in 2024, then slumped by 72.24% to $119.1 billion in 2025.
  • Its Receivables stands at $119.1 billion for Q3 2025, versus $3.5 million for Q1 2025 and $428.9 billion for Q3 2024.